Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J L SlackC D Bloomfield

Abstract

To examine, in newly diagnosed patients with acute promyelocytic leukemia (APL), the prognostic significance of secondary cytogenetic changes and the relationship between such changes and the two major promyelocytic leukemia-retinoic acid receptor alpha (PML-RAR alpha) mRNA types. One hundred sixty-one patients with t(15;17)(q22;q11-12) enrolled onto Cancer and Leukemia Group B (CALGB) protocol 8461, a prospective study of cytogenetics in acute myeloid leukemia (AML), were studied. Eighty of these 161 patients were treated solely with chemotherapy and evaluated for response to treatment and survival. PML-RAR alpha mRNA type was determined using reverse transcriptase polymerase chain reaction (RT-PCR) in 56 patients. The incidence of secondary cytogenetic abnormalities was 32%. Among 80 patients treated with chemotherapy, the presence of a secondary chromosome abnormality was associated with longer complete remission (CR) duration (median, 29.9 v 15.7 months; P = .03) and longer event-free survival (EFS) duration (median, 17.0 v 12.2 months; P = .03). There was no difference in overall survival (P = .28). In a separate group of 56 patients with both cytogenetic and molecular data, 32 had the type L PML-RAR alpha transcript (intr...Continue Reading

Citations

Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C K MurrayJ C Byrd
Nov 23, 2000·Proceedings of the National Academy of Sciences of the United States of America·D B ZimonjicT J Ley
Sep 19, 2001·Current Opinion in Hematology·J L PollockT J Ley
Nov 13, 2001·Oncogene·L Degos, Z Y Wang
Aug 7, 2002·Current Oncology Reports·Claudia Schoch, Torsten Haferlach
Dec 17, 2004·Molecular and Cellular Biology·Andrew A Lane, Timothy J Ley
Mar 12, 2015·Journal of Clinical Pathology·Xueya Zhang, Jingxin Pan
Mar 16, 2018·Oncology Letters·Can ChenShenxian Qian
Aug 7, 2002·Current Oncology Reports·Martin S Tallman, Chadi Nabhan
Feb 9, 2002·American Journal of Hematology·Shigeki ItohShin-ichiro Kuriya
Jan 25, 2002·Blood·Martin S TallmanJacob M Rowe
Oct 21, 2004·American Journal of Hematology·Ganesh C KudvaPaul J Petruska
Aug 21, 2007·Current Oncology Reports·Joseph G JurcicAnd Peter G Maslak
Jul 24, 2008·Journal of the National Cancer Institute. Monographs·Krzysztof Mrózek, Clara D Bloomfield
Apr 12, 2014·Expert Review of Hematology·Etienne De BraekeleerMarc De Braekeleer
May 15, 2003·Hematology·Vikas GuptaArmand Keating
Aug 26, 2003·Best Practice & Research. Clinical Haematology·Andres SirulnikJonathan D Licht
Jul 17, 2021·Hematology/oncology and Stem Cell Therapy·Minh Phuong VuHoang Vu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.